EUCTR2006-004030-32-DE进行中（未招募）1 期
Randomisierte Studie zur Wirksamkeit von FOLFIRI in Kombination mit Cetuximab vs. Bevacizumab in der Erstlinien-Behandlung des metastasierten kolorektalen KarzinomsEnglish translation:Randomised study for efficiency of FOLFIRI in combination with Cetuximab vs. Bevacizumab in first-line-therapy of metastatic colorectal cancer - FIRE-3
Klinikum der Ludwig-Maximilians Universität München, Klinikum Großhadern0 个研究点目标入组 800 人开始时间: 2006年11月9日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 800
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •-Histologically confirmed adenocarcinoma of colon and rectum
- •-confirmation of a K-RAS wild type status ( in the primary tumor or in metastasis)
- •-general condition: 0-2 (ECOG/ WHO)
- •-suitable for application of chemotherapy
- •-written informed consent (first and second-line therapy)
- •-Age 18- 75
- •-clinical or ambulant treatment
- •-Life expectancy > 3 months
- •-minimum one measurable indicator leasion according to RECIST. Evaluation
- •of tumor manifestation 2 weeks or less before study entry.
- •-Male or female patients with reproductive potential must use an approved
- •contraceptive method
- •-Leucocytes = 3,0 x 10\9/L with Neutrophils = 1,5 x 10\9/L, Thrombocytes =
- •100 10\9/L, Hemoglobin = 5,6 mmol/L equivalent to 9 g/dL
- •-Serum bilirubin = 1,5x upper NL
- •-ALAT and ASAT = 2,5 x upper NL, in case of liver metastases ALAT and
- •ASAT = 5 x upper NL.
- •-Serum creatinine = 1,5 x upper NL
- •-An operation has to take place 4 weeks before study entry; a fine needle
- •biopsy must have been performed more than 1 week ago. Wounds must
- •have completely healed. The necessity of a big operation in the course of
- •the study is not to be expected. An exception is a resection of liver
- •metastases. If there should be he option of a secondary curative
- •operation Bevacizumab has to be discontinued 6 to 8 weeks before
- •-relevant toxicitys of therapies prior must have abate
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- confirmation of a K-RAS mutation
- •-previous exposure to EGFR-targeting therapy
- •-previous treatment with Bevacizumab
- •-prior chemotherapy of colorectal cancer, except adjuvant chemotherapy
- •wich was terminated at least 6 month before study entry
- •-experimental medical treatment within 30 days before study entry
- •-known hypersensitivity to elements of the study drug
- •-pregnant (exclusion diagnosis by beta-hCG-test) or breast-feeding
- •-clinically relevant coronary disease or myocardial infarction within 12
- •months before study entry or enhanced risk of uncontrolled arrhythmia
- •-acute or subacute intestinal obstruction or chronical-inflammatory enteritis
- •during anamnesis or chronical diarrhea
- •-symptomatic peritoneal carcinosis
- •-serious, non-healing wounds, ulcera or bone fracture
- •-uncontrolled hypertonia
- •-pronounced proteinuria
- •-arterial thromboembolism or haemorrhage within 6 months before study
- •entry (except tumor bleeding before tumorresection)
- •-hemorrhagic diathesis or thrombotic tendency
- •-therapeutic anticoagulation (marcumar-therapy, PTT-effective
- •heparinization)
- •-known DPD-insufficience (special screening not necessary)
- •-known glucuronisation defect (Gilbert´s disease) (special screening not
- •-secondary malignancies during anamnesis within the last 5 years except
- •curatively treated basalioma or in situ carcinoma of the cervix
- •-known alcohol- or drug abuse
- •-clinical or psychological disorders that would prohibit to give a valid
- •informed consent or to perform the study
- •-a significant concomitant disorder which excludes the patient´s participation in from the
- •study in the opinion of the responsible physician
- •-absent or constricted legal capacity
研究者
相似试验
进行中（未招募）
1 期
Evaluation of the efficacy of a combinaison treatment based upon immunotherapy + chemotherapy to treat patient with a stomach cancerAdvanced gastric or gastro-oesophageal junction adenocarcinomaMedDRA version: 20.0 Level: LLT Classification code 10042080 Term: Stomach cancer System Organ Class: 100000004864MedDRA version: 20.0 Level: LLT Classification code 10026476 Term: Malignant neoplasm of stomach System Organ Class: 100000004864EUCTR2018-002014-13-FRFédération Francophone de Cancérologie Digestive94
进行中（未招募）
1 期
Comparison of chemotherapy with radiochemotherapy as treatment of patients with locally advanced, primarily inoperable pancreatic carcinomalocally advanced, primarily inoperable pancreatic carcinomaEUCTR2012-001850-24-ATABCSG (Austrian Breast & Colorectal Cancer Study Group)112
进行中（未招募）
1 期
A study with two treatment arms to assess the efficacy of FOLFIRI (chemotherapy regimen with folinic acid, fluorouracil and irinotecan) in combinations with one specific antibody (cetuximab vs. bevacizumab) in the first-line treatment of metastatic colorectal cancer.Metastatic colorectal cancerMedDRA version: 19.0Level: LLTClassification code 10052362Term: Metastatic colorectal cancerSystem Organ Class: 100000004864EUCTR2006-004030-32-ATKlinikum der Ludwig-Maximilians Universität München, Klinikum Großhadern568
进行中（未招募）
1 期
Randomised study to investigate FOLFOXIRI plus Cetuximab or FOLFOXIRI plus bevacizumab as first-line treatment of BRAF-mutated metastatic colorectal cancer (FIRE 4.5)Histologically confirmed, UICC stage IV adenocarcinoma of the colon or rectum with metastases (metastatic colorectal cancer, mCRC), primarily non-resectable or surgery refused by the patientRAS wild-type tumour status (KRAS and NRAS exons 2, 3, 4) (proven in the primary tumour or metastasis)BRAF-mutated (V600E) tumour (proven in the primary tumour or metastasis)MedDRA version: 21.0Level: LLTClassification code 10052362Term: Metastatic colorectal cancerSystem Organ Class: 100000004864EUCTR2015-004849-11-DEniversity Clinic od Munich-Großhadern (represented by the medical management)108
进行中（未招募）
不适用
A randomized phase II study of FOLFORI plus or not CETUXIMAB in elderly advanced colorectal cancer patients.Elderly mestatic colorectal cancer patients, Wild-type KRAS ,70-80 years of age, ECOG 0-1.MedDRA version: 14.1Level: SOCClassification code 10029104Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps)System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-000477-23-ITAZIENDA OSPEDALIERO UNIVERSITARIA OSPEDALI RIUNITI UMBERTO I - G.M.LANCISI - G.SALESI